These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 18473301

  • 1. [The role of angiogenesis in renal carcinoma].
    Bussolati B, Satolli MA, Camussi G.
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [Abstract] [Full Text] [Related]

  • 2. [Angiogenesis and renal cell carcinoma].
    Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [Abstract] [Full Text] [Related]

  • 3. [Angiogenesis targeting in renal carcinomas].
    Pouessel D, Culine S.
    Bull Cancer; 2007 Jul; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI.
    Clin Cancer Res; 2007 Feb 15; 13(4):1098-106. PubMed ID: 17317817
    [Abstract] [Full Text] [Related]

  • 5. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ, Rohde D, Peter S.
    Aktuelle Urol; 2010 Jan 15; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [Abstract] [Full Text] [Related]

  • 6. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ, Bukowski RM.
    J Clin Oncol; 2006 Dec 10; 24(35):5601-8. PubMed ID: 17158546
    [Abstract] [Full Text] [Related]

  • 7. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A.
    Orv Hetil; 2011 Apr 24; 152(17):655-62. PubMed ID: 21464023
    [Abstract] [Full Text] [Related]

  • 8. Molecular biology of renal cell carcinoma.
    Mellado B, Gascón P.
    Clin Transl Oncol; 2006 Oct 24; 8(10):706-10. PubMed ID: 17074668
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 24; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 10. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E, Medioni J, Scotte F, Ayllon J, Mejean A, Cuenod CA, Tartour E, Elaidi R, Oudard S.
    Bull Cancer; 2010 Sep 24; 97():29-43. PubMed ID: 20418202
    [Abstract] [Full Text] [Related]

  • 11. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.
    J Urol; 2008 Sep 24; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [Abstract] [Full Text] [Related]

  • 12. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B.
    Cancer J; 2008 Sep 24; 14(5):325-9. PubMed ID: 18836338
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Rini BI.
    Cancer; 2009 May 15; 115(10 Suppl):2306-12. PubMed ID: 19402073
    [Abstract] [Full Text] [Related]

  • 14. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I.
    Magy Onkol; 2007 May 15; 51(2):145-53. PubMed ID: 17660871
    [Abstract] [Full Text] [Related]

  • 15. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D, Culine S, Verhoest G, Patard JJ.
    Presse Med; 2008 Apr 15; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [Abstract] [Full Text] [Related]

  • 16. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI.
    Curr Oncol Rep; 2006 Mar 15; 8(2):85-9. PubMed ID: 16507216
    [Abstract] [Full Text] [Related]

  • 17. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Rini BI.
    Expert Rev Anticancer Ther; 2006 Dec 15; 6(12):1753-60. PubMed ID: 17181489
    [Abstract] [Full Text] [Related]

  • 18. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Sire M, Wallerand H, Kilkoski F, Grenier N, Ferrière JM, Ravaud A.
    Bull Cancer; 2008 Sep 15; 95(9):813-20. PubMed ID: 18829413
    [Abstract] [Full Text] [Related]

  • 19. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J.
    N Engl J Med; 2007 Jan 11; 356(2):185-7. PubMed ID: 17215538
    [No Abstract] [Full Text] [Related]

  • 20. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK, Papadopoulos G.
    J BUON; 2009 Jan 11; 14(3):399-404. PubMed ID: 19810129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.